NCT04873492Recruiting
From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis
Source: ClinicalTrials.gov · Last updated 19 Mar 2026
Brief summary (registry, in English)
MS is a heterogeneous disease either in its response to treatment or clinical manifestation. Indeed, the natural history of MS is varying from a benign condition to a devastating and rapidly incapacitating disease. Clinical heterogeneity could also be cellular and / or molecular. The aim is to identify from OMIC analyses, at the early stage of the disease, differentially expressed molecules and / or cell subpopulations derived from CD8 + T lymphocytes and / or CD4 + T lymphocytes and / or B lymphocytes and monocytes from patients with aggressive versus non-aggressive, compared to a cohort of healthy controls
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 130 (estimated)
- First submitted
- 30 Apr 2021
- Start date
- 24 Jan 2022
- Primary completion date
- 24 Jul 2029
- Lead sponsor
- Nantes University Hospital
- Diseases
- Multiple sclerosis
- NCT number
- NCT04873492
What you commit to
- Study type: Interventional
- Planned participants: 130
- From 24 Jan 2022 to the primary completion date, 24 Jul 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Immunosuppressive drug at the time of blood collection
- Plasma exchange or corticosteroid treatment within the four weeks prior to blood sample
Other
- Ongoing participation to a another study
- Refusal to genetic analyses
- Adults under a legal protection regime (guardianship, trusteeship, judicial safeguard)
- Pregnancy
Who the study is looking for
- Common criteria for retrospective MS patients:
- Patients aged 18 years or older
- Clinical isolated syndrome (CIS) with or without dissemination in space
- Patients affiliated to an appropriate health insurance
- Criteria for Aggressive MS group
- Start of a 2nd line therapy within the two years following the CIS
- Criteria for Non aggressive MS group
- No conversion according to McDonald criteria from clinical isolated syndrome to multiple sclerosis within 2 years or
- Conversion based to McDonald criteria treated or not with first line disease modifying therapy within 2 years.
- Have a minimum of least 2 years of follow-up.
- Healthy volunteers
- Aged 18 years or older
- No history of clinically isolated syndrome or MS
- Pairing criteria :
- Age +/- 5 years
- Sex
- Prospective MS Patients
- Patients aged 18 years or older
- Clinical isolated syndrome (CIS) with or without dissemination in space
- Patients affiliated to an appropriate health insurance
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nantes University Hospital Coordinator of this site? Confirm its status | Nantes | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.